Can a cancer drug protect new kidneys from scarring?

NCT ID NCT06751602

ENROLLING_BY_INVITATION Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding belumosudil (Rezurock) to standard care can prevent scarring in new kidney transplants. About 40 adults receiving their first or second kidney will be randomly assigned to get the drug or a placebo for a year. The study tracks serious side effects and checks kidney tissue for scarring at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belumosudil (also known as Rezurock)
What this could lead to: If it works, this could point toward a way to prevent kidney scarring and extend transplant life without increasing rejection risk.
What could go wrong: This is a small, early-phase trial (40 people) testing a drug already approved for another condition. It may not show benefit, and side effects could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic transplant rejection end stage renal failure pulmonary fibrosis interstitial nephritis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REJECTION CHRONIC RENAL

Contacts and locations

Locations

Houston Methodist Research Institute

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.